Cargando…
Granulibacter bethesdensis, a Pathogen from Patients with Chronic Granulomatous Disease, Produces a Penta-Acylated Hypostimulatory Glycero-D-talo-oct-2-ulosonic Acid–Lipid A Glycolipid (Ko-Lipid A)
Granulibacter bethesdensis can infect patients with chronic granulomatous disease, an immunodeficiency caused by reduced phagocyte NADPH oxidase function. Intact G. bethesdensis (Gb) is hypostimulatory compared to Escherichia coli, i.e., cytokine production in human blood requires 10–100 times more...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8036547/ https://www.ncbi.nlm.nih.gov/pubmed/33804872 http://dx.doi.org/10.3390/ijms22073303 |
_version_ | 1783676935713325056 |
---|---|
author | Muszyński, Artur Zarember, Kol A. Heiss, Christian Shiloach, Joseph Berg, Lars J. Audley, John Kozyr, Arina Greenberg, David E. Holland, Steven M. Malech, Harry L. Azadi, Parastoo Carlson, Russell W. Gallin, John I. |
author_facet | Muszyński, Artur Zarember, Kol A. Heiss, Christian Shiloach, Joseph Berg, Lars J. Audley, John Kozyr, Arina Greenberg, David E. Holland, Steven M. Malech, Harry L. Azadi, Parastoo Carlson, Russell W. Gallin, John I. |
author_sort | Muszyński, Artur |
collection | PubMed |
description | Granulibacter bethesdensis can infect patients with chronic granulomatous disease, an immunodeficiency caused by reduced phagocyte NADPH oxidase function. Intact G. bethesdensis (Gb) is hypostimulatory compared to Escherichia coli, i.e., cytokine production in human blood requires 10–100 times more G. bethesdensis CFU/mL than E. coli. To better understand the pathogenicity of G. bethesdensis, we isolated its lipopolysaccharide (GbLPS) and characterized its lipid A. Unlike with typical Enterobacteriaceae, the release of presumptive Gb lipid A from its LPS required a strong acid. NMR and mass spectrometry demonstrated that the carbohydrate portion of the isolated glycolipid consists of α-Manp-(1→4)-β-GlcpN3N-(1→6)-α-GlcpN-(1⇿1)-α-GlcpA tetra-saccharide substituted with five acyl chains: the amide-linked N-3′ 14:0(3-OH), N-2′ 16:0(3-O16:0), and N-2 18:0(3-OH) and the ester-linked O-3 14:0(3-OH) and 16:0. The identification of glycero-d-talo-oct-2-ulosonic acid (Ko) as the first constituent of the core region of the LPS that is covalently attached to GlcpN3N of the lipid backbone may account for the acid resistance of GbLPS. In addition, the presence of Ko and only five acyl chains may explain the >10-fold lower proinflammatory potency of GbKo–lipidA compared to E. coli lipid A, as measured by cytokine induction in human blood. These unusual structural properties of the G.bethesdensis Ko–lipid A glycolipid likely contribute to immune evasion during pathogenesis and resistance to antimicrobial peptides. |
format | Online Article Text |
id | pubmed-8036547 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-80365472021-04-12 Granulibacter bethesdensis, a Pathogen from Patients with Chronic Granulomatous Disease, Produces a Penta-Acylated Hypostimulatory Glycero-D-talo-oct-2-ulosonic Acid–Lipid A Glycolipid (Ko-Lipid A) Muszyński, Artur Zarember, Kol A. Heiss, Christian Shiloach, Joseph Berg, Lars J. Audley, John Kozyr, Arina Greenberg, David E. Holland, Steven M. Malech, Harry L. Azadi, Parastoo Carlson, Russell W. Gallin, John I. Int J Mol Sci Article Granulibacter bethesdensis can infect patients with chronic granulomatous disease, an immunodeficiency caused by reduced phagocyte NADPH oxidase function. Intact G. bethesdensis (Gb) is hypostimulatory compared to Escherichia coli, i.e., cytokine production in human blood requires 10–100 times more G. bethesdensis CFU/mL than E. coli. To better understand the pathogenicity of G. bethesdensis, we isolated its lipopolysaccharide (GbLPS) and characterized its lipid A. Unlike with typical Enterobacteriaceae, the release of presumptive Gb lipid A from its LPS required a strong acid. NMR and mass spectrometry demonstrated that the carbohydrate portion of the isolated glycolipid consists of α-Manp-(1→4)-β-GlcpN3N-(1→6)-α-GlcpN-(1⇿1)-α-GlcpA tetra-saccharide substituted with five acyl chains: the amide-linked N-3′ 14:0(3-OH), N-2′ 16:0(3-O16:0), and N-2 18:0(3-OH) and the ester-linked O-3 14:0(3-OH) and 16:0. The identification of glycero-d-talo-oct-2-ulosonic acid (Ko) as the first constituent of the core region of the LPS that is covalently attached to GlcpN3N of the lipid backbone may account for the acid resistance of GbLPS. In addition, the presence of Ko and only five acyl chains may explain the >10-fold lower proinflammatory potency of GbKo–lipidA compared to E. coli lipid A, as measured by cytokine induction in human blood. These unusual structural properties of the G.bethesdensis Ko–lipid A glycolipid likely contribute to immune evasion during pathogenesis and resistance to antimicrobial peptides. MDPI 2021-03-24 /pmc/articles/PMC8036547/ /pubmed/33804872 http://dx.doi.org/10.3390/ijms22073303 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ). |
spellingShingle | Article Muszyński, Artur Zarember, Kol A. Heiss, Christian Shiloach, Joseph Berg, Lars J. Audley, John Kozyr, Arina Greenberg, David E. Holland, Steven M. Malech, Harry L. Azadi, Parastoo Carlson, Russell W. Gallin, John I. Granulibacter bethesdensis, a Pathogen from Patients with Chronic Granulomatous Disease, Produces a Penta-Acylated Hypostimulatory Glycero-D-talo-oct-2-ulosonic Acid–Lipid A Glycolipid (Ko-Lipid A) |
title | Granulibacter bethesdensis, a Pathogen from Patients with Chronic Granulomatous Disease, Produces a Penta-Acylated Hypostimulatory Glycero-D-talo-oct-2-ulosonic Acid–Lipid A Glycolipid (Ko-Lipid A) |
title_full | Granulibacter bethesdensis, a Pathogen from Patients with Chronic Granulomatous Disease, Produces a Penta-Acylated Hypostimulatory Glycero-D-talo-oct-2-ulosonic Acid–Lipid A Glycolipid (Ko-Lipid A) |
title_fullStr | Granulibacter bethesdensis, a Pathogen from Patients with Chronic Granulomatous Disease, Produces a Penta-Acylated Hypostimulatory Glycero-D-talo-oct-2-ulosonic Acid–Lipid A Glycolipid (Ko-Lipid A) |
title_full_unstemmed | Granulibacter bethesdensis, a Pathogen from Patients with Chronic Granulomatous Disease, Produces a Penta-Acylated Hypostimulatory Glycero-D-talo-oct-2-ulosonic Acid–Lipid A Glycolipid (Ko-Lipid A) |
title_short | Granulibacter bethesdensis, a Pathogen from Patients with Chronic Granulomatous Disease, Produces a Penta-Acylated Hypostimulatory Glycero-D-talo-oct-2-ulosonic Acid–Lipid A Glycolipid (Ko-Lipid A) |
title_sort | granulibacter bethesdensis, a pathogen from patients with chronic granulomatous disease, produces a penta-acylated hypostimulatory glycero-d-talo-oct-2-ulosonic acid–lipid a glycolipid (ko-lipid a) |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8036547/ https://www.ncbi.nlm.nih.gov/pubmed/33804872 http://dx.doi.org/10.3390/ijms22073303 |
work_keys_str_mv | AT muszynskiartur granulibacterbethesdensisapathogenfrompatientswithchronicgranulomatousdiseaseproducesapentaacylatedhypostimulatoryglycerodtalooct2ulosonicacidlipidaglycolipidkolipida AT zaremberkola granulibacterbethesdensisapathogenfrompatientswithchronicgranulomatousdiseaseproducesapentaacylatedhypostimulatoryglycerodtalooct2ulosonicacidlipidaglycolipidkolipida AT heisschristian granulibacterbethesdensisapathogenfrompatientswithchronicgranulomatousdiseaseproducesapentaacylatedhypostimulatoryglycerodtalooct2ulosonicacidlipidaglycolipidkolipida AT shiloachjoseph granulibacterbethesdensisapathogenfrompatientswithchronicgranulomatousdiseaseproducesapentaacylatedhypostimulatoryglycerodtalooct2ulosonicacidlipidaglycolipidkolipida AT berglarsj granulibacterbethesdensisapathogenfrompatientswithchronicgranulomatousdiseaseproducesapentaacylatedhypostimulatoryglycerodtalooct2ulosonicacidlipidaglycolipidkolipida AT audleyjohn granulibacterbethesdensisapathogenfrompatientswithchronicgranulomatousdiseaseproducesapentaacylatedhypostimulatoryglycerodtalooct2ulosonicacidlipidaglycolipidkolipida AT kozyrarina granulibacterbethesdensisapathogenfrompatientswithchronicgranulomatousdiseaseproducesapentaacylatedhypostimulatoryglycerodtalooct2ulosonicacidlipidaglycolipidkolipida AT greenbergdavide granulibacterbethesdensisapathogenfrompatientswithchronicgranulomatousdiseaseproducesapentaacylatedhypostimulatoryglycerodtalooct2ulosonicacidlipidaglycolipidkolipida AT hollandstevenm granulibacterbethesdensisapathogenfrompatientswithchronicgranulomatousdiseaseproducesapentaacylatedhypostimulatoryglycerodtalooct2ulosonicacidlipidaglycolipidkolipida AT malechharryl granulibacterbethesdensisapathogenfrompatientswithchronicgranulomatousdiseaseproducesapentaacylatedhypostimulatoryglycerodtalooct2ulosonicacidlipidaglycolipidkolipida AT azadiparastoo granulibacterbethesdensisapathogenfrompatientswithchronicgranulomatousdiseaseproducesapentaacylatedhypostimulatoryglycerodtalooct2ulosonicacidlipidaglycolipidkolipida AT carlsonrussellw granulibacterbethesdensisapathogenfrompatientswithchronicgranulomatousdiseaseproducesapentaacylatedhypostimulatoryglycerodtalooct2ulosonicacidlipidaglycolipidkolipida AT gallinjohni granulibacterbethesdensisapathogenfrompatientswithchronicgranulomatousdiseaseproducesapentaacylatedhypostimulatoryglycerodtalooct2ulosonicacidlipidaglycolipidkolipida |